Paper Report for: Sonali_2013_Dement.Geriatr.Cogn.Disord_37_58
Reference
Title: Impact of CYP2D6 and CYP3A4 Genetic Polymorphism on Combined Cholinesterase Inhibitors and Memantine Treatment in Mild to Moderate Alzheimer's Disease Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V Ref: Dementia & Geriatric Cognitive Disorders, 37:58, 2013 : PubMed
Aim: The impact of CYP2D6 and CYP3A4 polymorphism on the steady-state plasma concentrations and therapeutic outcome of donepezil monotherapy and combination therapy in Alzheimer's disease (AD) patients. Methods: A total of 38 patients for donepezil and 17 patients for donepezil and memantine therapy, aged >/=55 years, were recruited meeting inclusion and exclusion criteria. Polymerase chain reaction-restriction fragment length polymorphism was performed. The liquid chromatography-tandem mass spectrometry method was used for estimation of drug levels of donepezil and memantine. Results: Significant allele frequency was observed for CYP2D6*3 polymorphism in patients on donepezil monotherapy and combination therapy. Significant allele frequency for CYP2D6*4 was observed in the patients on donepezil monotherapy. Conclusion: CYP2D6 polymorphism, though not significant, might partially be involved in the plasma concentration of AD drug. (c) 2013 S. Karger AG, Basel.
        
Related information
Citations formats
Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V (2013) Impact of CYP2D6 and CYP3A4 Genetic Polymorphism on Combined Cholinesterase Inhibitors and Memantine Treatment in Mild to Moderate Alzheimer's Disease Dementia & Geriatric Cognitive Disorders37: 58-70
Sonali N, Tripathi M, Sagar R, Velpandian T, Subbiah V (2013) Dementia & Geriatric Cognitive Disorders37: 58-70